Keryx Biopharm Inc (KERX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2017 | 12-2016 | 12-2015 | 12-2014 | 12-2013 | |
| Sales | 60,641 | 31,983 | 13,680 | 10,825 | 7,000 |
| Cost of Goods | 25,031 | 40,689 | 6,644 | 495 | N/A |
| Gross Profit | 35,610 | -8,706 | 7,036 | 10,330 | 7,000 |
| Operating Expenses | 137,332 | 114,746 | 118,748 | 122,054 | 54,083 |
| Operating Income | -101,691 | -122,763 | -111,068 | -111,229 | -47,083 |
| Other Income | -61,984 | -38,252 | -11,987 | 411 | 351 |
| Pre-tax Income | -163,675 | -161,015 | -123,055 | -110,818 | -46,732 |
| Income Tax | -235 | 80 | 90 | 700 | N/A |
| Net Income Continuous | -163,440 | -161,095 | -123,145 | -111,518 | -46,732 |
| Net Income | $-163,440 | $-161,095 | $-123,145 | $-111,518 | $-46,732 |
| EPS Basic Total Ops | -1.43 | -1.52 | -1.19 | -1.23 | -0.58 |
| EPS Basic Continuous Ops | -1.43 | -1.52 | -1.19 | -1.23 | -0.58 |
| EPS Diluted Total Ops | -1.43 | -1.52 | -1.19 | -1.23 | -0.58 |
| EPS Diluted Continuous Ops | -1.43 | -1.52 | -1.19 | -1.23 | -0.58 |
| EPS Diluted Before Non-Recurring Items | -0.88 | -1.35 | -1.19 | -1.23 | -0.58 |
| EBITDA(a) | $-38,033 | $-87,775 | $-99,278 | $-110,923 | $-47,029 |